Protocols
POLARIS-2022-001-ARGSARC Phase III OPEN TO ACCRUAL
ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial